Breaking News on Drug Discovery |
All news articles > May 2005
| « Previous month | Next month » |
31-May-2005
Qiagen acquisition extends diagnostics range
Qiagen has acquired the PCR diagnostics company Artus, in a move that now allows Qiagen to offer preanalytical sample preparation and diagnostic assay solutions to its partners in molecular diagnostics. The acquisition further allows Qiagen to broadening the tests available on current diagnostic platforms fuelling growth in molecular diagnostics.
Pfizer enters VR1 deal with Renovis
Pfizer has entered a worldwide collaboration and licensing agreement with Renovis to research, develop and commercialise small molecules that target a receptor, which generates signals for certain types of pain.
30-May-2005
Ablynx signs Nanobodies NRC deal
Ablynx has announced that it had signed a collaborative agreement with the National Research Council of Canada (NRC) Institute for Biological Sciences (IBS) that aims to concentrate its discovery efforts in the area of neurodegenerative diseases.
Targeted Genetics granted AAV patent
Targeted Genetics Corporation announced the issuance of a new patent, which covers the company's approach to increase carrying capacity of adeno-associated virus (AAV) technology platform expanding the potential applications of AAV-based gene delivery.
Whistleblowers reveal FDA exacerbated Vioxx scandal
An official of the Food and Drug Administration (FDA) has admitted that the regulatory agency was "the single greatest obstacle to doing anything effective" regarding Vioxx, adding that the FDA could have prevented the deaths resulting from the drug's use.
Isis presents next-gen asthma drug data
According to data presented this week, multiple second-generation antisense drugs that show potential as new treatments for asthma could represent the future in treating this disorder that has soared in worldwide cases, particularly amongst children.
Researchers identify gene enzymatic activity
US researchers have identified an enzyme activity that is inactivated in all reported mutant forms of a disease protein, opening up opportunities for therapies to treat ataxia, a rare hereditary neurological disease that affects 1/100,000 people worldwide.
New software identifies scientific trends
Chemical Abstracts Service and FIZ Karlsruhe have launched new software that is set to provide insights into trends and patterns in scientific and patent information, which is achievable through greater value from search results.
27-May-2005
NanoLogix unveils DNA extraction system
NanoLogix unveils its DNA extraction system for the molecular diagnostics market, which is said to take significantly less time than standard spin column extraction methods.
26-May-2005
Novartis expands Myogen CV collaboration
Novartis'collaboration with Myogen looks to have been a shrewd move as Myogen report the extension to the original agreement to include its histone deacetylase inhibitor (HDACi) program. In addition, Myogen has achieved three development milestones for the discovery and development of novel drugs for cardiovascular disease.
New Honeybee system creates industry buzz
Genomic Solutions launches proprietary technology that automates and minitaturises protein crystallisation screening, dispensing both precipitant/mother liquors and protein in volumes ranging from 100 nanolitres to 100 microlitres.
Report describes bioinformatics market as 'explosive'
According to a recent report, the global bioinformatics market is currently estimated at about $1.4 billion (€1.1 billion). It is expected to grow at an average annual growth rate of 15.8 per cent to reach nearly $3 billion by 2010, reflecting bioinformatics' explosive growth in cheminformatics and pharmacogenomics.
25-May-2005
Report recommends animal experiment alternatives
A two-year study has recommended a greater focus in looking for other methods of conducting medical research, as the continued use of animals in experiments is both unrealistic and ethically controversial.
Merck Scottish operation relocates to US
Merck KGaA announced its intention to relocate its pharmaceutical research operations in Scotland to its larger biotech research facility in the United States, withdrawing its DeImmunisation technology service at the same time.
24-May-2005
Qiagen launches automated purification kits
Qiagen has released two protein purification kits that provide affordable automation as a way to increase throughput and free up valuable manpower for less routine tasks.
Editors reiterate trial registration call
Editors of eleven international medical journals have amplified their call for the registration of drug trials before the first patient is enrolled,in a medium that is fully searchable and publicly accessible at no charge.
UK approves Ab trial for HIV/AIDS
BioInvent become the latest company to enter the HIV/AIDS drug arena after UK authorities gave the go ahead to commence the company's first clinical trial of its human antibody to treat the virus.
23-May-2005
Evident launch quantum dot world first
Evident Technologies has launched the world's first commercially available non-heavy metal quantum dot (QD) reagents that are less toxic to cells.
Marketing solutions managers and business developers sought
Novis Pharmaceutical and Science Division (UK) is looking for three strong sales and business developers to take our award winning daily online news services to the next level.
Polysaccharide combats cancer drug resistance
Scientists have reported that a molecule previously thought to play a purely structural and inert role in cells may play a key role in bringing about multidrug resistance in cancer.
GSK opens Centre of Excellence
GlaxoSmithKline (GSK) has created a Centre of Excellence for External Drug Discovery (CEEDD) that aims to provide GSK with alternative scientific and drug discovery approaches. The CEEDD also aims to exploit the full potential of GSK's R&D assets to generate more targets and compounds.
399 new medicines in development to treat cancer
According to a new survey, there are currently 399 new medicines in development now to treat cancer. The survey shows that many of these medicines represent potential breakthrough cancer treatments, while others involve possible new uses for existing medicines.
Biogen identifies CNS repair molecule
Biotechnology company, Biogen has announced the identification of a molecule that may play a key role in the repair and regeneration of the central nervous system (CNS). The finding could lead to potential pathways for treating multiple sclerosis (MS) and other demyelinating diseases.
20-May-2005
Researchers develop enhanced cancer model
US researchers have developed the first animal model that clearly defines cancer metastasises in all the same places that human pancreatic cancer spreads to such as the liver, lungs, diaphragm, and adrenal glands.
Report identifies shift towards personalised medicine
According to a new report the struggle to meet the escalating health problem of an increasingly ageing population is being replaced by a focus on treatment that prevents or delays the onset of disease, personalising medicine to each individual.
19-May-2005
Researchers hail incretin as next diabetic treatment
A new understanding of specialised gut hormones may lead to advances in the treatment and management of type 2 diabetes, offering patients a viable option in controlling fluctuating blood glucose levels that is characteristic of the disease.
ASCO unveils latest treatment strategies
In the wake of the latest American Society of Clinical Oncology's (ASCO) annual conference, drug companies from around the world showcased potential drug treatments, with a number of new molecular targets as well as therapy strategies for cancer.
Affitech enters cancer antibody deal
Biotechnology company, Affitech, has entered into a collaboration agreement for two promising new cancer-specific human antibodies using its Cell-Based Antibody Selection technology (CBAS).
18-May-2005
GS identifies strong 2005 osteoporosis pipeline
Osteoporosis, which has developed into a multibillion-dollar market, and is dominated by Merck's Fosamax and Proctor & Gamble/Sanofi-Aventis' Actonel, now faces new competition after the Food and Drug Administration (FDA) approved new treatments that enter this market forecasted to reach $10.4 billion (€8.2 billion) by 2011.
ArQule reports anti-tumour efficacy at ASCO
Biotechnology company, ArQule, have reported evidence of anti-tumour activity of its drug candidate that has a mechanism of action based on its Activated Checkpoint Therapy (ACT) platform and represents the latest monotherapeutic strategy to treat cancer.
Qiagen enters protein glycoanalysis deal
Qiagen and Procognia have entered into a marketing and licensing agreement, which targets the emerging field of protein glycoanalysis. The combination of Qproteome products with Procognia's On-Chip Glycoanalysis technology aims to create a host of "guided fractionation" solutions.
MedImmune presents positive MAb data
MedImmune has announced Phase I clinical trial results of an antibody that appeared to be safe and well tolerated in patients with certain T-cell lymphomas and leukemias. The results signify the emergence of monoclonal antibodies (MAb) as viable and effective treatments, rivalling small molecule therapeutics.
17-May-2005
Editor claims pharma exploit med journals
A former editor of the British Medical Journal (BMJ) claims that medical journals are an extension of the marketing arm of pharmaceutical companies, placing editors in difficult positions as company-funded trials are becoming increasingly popular.
16-May-2005
Agilent opens Shanghai science training centre
Agilent Technologies is to open a new Life Sciences and Chemical Analysis (LSCA) technical training centre in Shanghai in a move that reflects the current trend for biotech companies to divert resources to offshoring operations.
Qiagen enter DNA methylation collaboration
Qiagen and Epigenomics have entered into a collaboration to jointly develop and introduce preanalytical solutions for DNA methylation analysis to focus on in-vitro diagnosis (IVD) and pharmacogenomics markets.
Biomarker indicates patient susceptibility to treatment
According to a latest study, which revealed the presence of a unique genetic biomarker, the quality of life for patients undergoing treatment for colorectal cancer may be significantly improved, potentially minimising the unwanted side effects.
InterMune presents encouraging HCV drug data
Intermune has announced the results of preclinical data on the specificity and tolerability of two potent and selective small molecule inhibitors of the hepatitis C virus (HCV). The findings are significant, as they have previously been shown to be highly potent, metabolically stable and orally available.
Genevac speeds up lab-scale freeze-drying
Genevac has introduced new technology for its Model HT-4X centrifugal evaporator whereby the system can be used to accelerate lyophilisation of water and water mixtures by as much as three hundred per cent.
Applied Bio named top mass spec supplier
According to a new report, Applied Biosystems/MDS Sciex is the leading mass spectrometer brand in all regions and market segments. Suppliers in this market will benefit from the 19 per cent of mass spectrometer users surveyed who plan to purchase a new instrument within the next year.
13-May-2005
Researchers discover new way to fight asthma
Researchers may have found a novel way to fight asthma by targeting a protein that is centrally involved in the bronchial inflammation and airway constriction that prompts asthma's hallmark symptoms. The antibody treatment is one of a new class of drugs called complement inhibitors.
Integration of dual autosampler optimises HPLC system
Eksigent Technologies introduces a new range of software drivers and hardware accessories that ensure sample delivery at a pace that improves the throughput of its eight-channel HPLC system.
12-May-2005
GenVault acquires nucleic acid labelling patent
Biosample management firm, GenVault announced an exclusive agreement to acquire the full rights to a DNA labelling intellectual property, which allows researchers to identify the sample through its complete downstream analysis to maintain a permanent chain of custody.
Report urges US to attract outstanding researchers
According to a new report by the National Academies, the advent of increased global competition for outstanding students and scientists has heightened the need for a widespread effort to attract high calibre researchers to the US.
11-May-2005
Vertex reports potency for hep C treatment
Vertex Pharmaceuticals have announced the latest results that indicate the investigational oral hepatitis C virus (HCV) protease inhibitor VX-950 was well tolerated and demonstrated potent antiviral activity in a Phase Ib clinical trial.
Deal sees PSMA mAb development for cancer
Biopharmaceutical company, Cytogen, and contract services provider Dowpharma have announced a collaboration to create a targeted oncology product designed to treat prostate and other cancers. The new treatment also demonstrates the progression monoclonal antibodies have made as a viable pharmaceutical therapy.
Therapeutic antibodies realise commercial potential
According to a new report the therapeutic antibody market is expected to treble in size by 2010 as significant leaps forward coupled with safer and more effective humanised and fully human antibodies are pouring onto the market fulfilling their long-awaited commercial promise.
Mederex initiates ulcerative colitis phase I trial
Medarex has announced the initiation of a phase I clinical trial of its human monoclonal antibody for the treatment of ulcerative colitis after the FDA granted the company an Investigational New Drug (IND) application.
10-May-2005
Wyatt offers light scattering product range
Wyatt Technology is set to offer its first integrated solution for batch dynamic light scattering, which are amongst a batch of products set to bring improved high throughput screening and better understanding of the physical attributes of purified protein molecules.
09-May-2005
Sangamo initiates diabetic neuropathy trial
Sangamo BioSciences has initiated a Phase I clinical trial for its novel therapy for diabetic neuropathy that is designed to protect and stimulate the regeneration of peripheral nerve function in diabetics suffering from peripheral neuropathy.
Arrayjet launches new microarray spotter
Arrayjet launches a new inkjet microarray spotter, which uses a modern, replaceable inkjet print head with over 100 nozzles to deliver samples to the array surface. The non-contact technology also has a unique replaceable inject print head for uniformity and consistency.
Mouse tool offers new disease insights
A new laboratory technique used by fruit fly geneticists for more than a decade is now available to scientists studying genes and diseases in mice. This technique offers a powerful new tool to study genetics, particularly in disease.
Research suggests new tumour treatment
US researchers think they have found promising new molecular targets and treatment approaches for malignant brain tumours, suggesting a new therapy for anti-cancer drugs.
Arena issued with obesity patent
A patent has been issued to Arena Pharmaceuticals for its small molecule treatment for obesity, which targets a specific receptor, thought to be involved in the regulation of food intake and may be useful in pharmaceutical compositions for the treatment of the condition.
04-May-2005
Bio-Tek and LI-COR strike microplate stacker deal
Bio-Tek Instruments and LI-COR Biosciences announce the integration of Bio-Tek's Bio-Stack Microplate Stacker to LI-COR's new Aerius Automated Infrared Imaging System, a microplate reader providing automated data analysis of In-Cell Westerns.
Charles River 1Q reflects outsourcing trend
Charles River Laboratories saw a double-digit boost in fiscal first quarter revenues reflecting a jump in operating earnings, helped by its acquisition of Inveresk Research Group and the emerging trend in outsourcing preclinical services.
03-May-2005
VEGF inhibitor effective in treating eye disease
Eyetech Pharmaceuticals' latest study has demonstrated the significance of VEGF164 in pathological neovascularisation, providing further evidence of the therapeutic benefits of a VEGF inhibitor that specifically targets an underlying cause of eye disease.
VIRxSYS completes HIV gene therapy study
VIRxSYS has announced the completion of the phase I study of its novel HIV gene therapy, which has been touted as the first of a next-generation anti-HIV treatment involving gene therapy. The positive results mean a phase II study will be initiated.
Qiagen acquires RNAture portfolio
Qiagen has announced the acquisition of RNAture's nucleic acid isolation products from Hitachi Chemical Research Centre. The latest acquisition sees Qiagen purchase an extensive range of products that addresses high-throughput mRNA purification for gene analysis.
02-May-2005
Celera files IND for novel cancer inhibitor
Celera Genomics have filed an Investigational New Drug (IND) application for a novel histone deacetylase (HDAC) inhibitor that has proved effective in inhibiting cancer cell proliferation. The filing also signifies Celera's transformation from selling data to focusing on the realisation of downstream value in targeted medicine.
Serono and Genmab sign mab agreement
A worldwide agreement to develop and commercialise a fully human monoclonal antibody that could have therapeutic potential in the treatment of T-cell mediated diseases has been agreed between Serono and Genmab.
Waters launches MassTrak Clinical Solutions
Waters Corporation has launched the MassTrak Clinical Solutions, a system that is aimed at monitoring and measuring drug therapies, performing toxicology screening and quantifying biomarkers quickly, reliably and accurately.
Blocking COX-1 slows mice tumour growth
Researchers in the US have found that blocking the COX-1, not COX-2 enzyme, might lead the way to prevent and treat the most common and fatal form of ovarian cancer.
GSK acquires Corixa for €233m
GlaxoSmithKline has announced plans to acquire the Corixa Corporation, which represents an important strategic deal for GSK's vaccines division, GSK Bio. The division is the only major vaccine maker with active R&D programs for HIV, malaria, and TB and are currently in late development for vaccines against rotavirus and strepto pneumonia.
| « Previous month | Next month » |
© 2000/2009 - Decision News Media SAS - All right reserved.
